Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 21, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia Therapeutics stock price declined after announcing halt of NTLA-3001 research and 27% workforce reduction, potentially signaling strategic shifts and financial challenges.
The lawsuit and company announcement suggest significant operational challenges, research discontinuation, and potential financial strain, which are likely to negatively impact investor sentiment and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100